Breast cancer is one of those illnesses that it pays to know at least as much about as your doctor does. There's always a new study, a conflicting report or an experimental treatment to consider. Take last week's carefully worded advice about two anticancer drugs sent to the U.S. Food and Drug Administration by a panel of experts. If you don't pay close attention to the details, you could wind up doing yourself more harm than good.
In the first case, the advisory panel recommended that the FDA expand its current approval of the breast-cancer drug tamoxifen to include women who...
To continue reading:
or
Log-In
